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Abstract 
Background:   
Catheter ablation of PVCs is highly successful and has become the hallmark treatment for 
symptomatic or highly prevalent cases.  However, few studies exist that evaluate the outcomes of 
ablation and likely mechanisms of PVC recurrence beyond 1 year of follow-up. 
Methods and Results: 
This study is a retrospective analysis of patients who underwent catheter ablation for symptomatic 
PVCs with acute procedural success and had clinical follow-up ≥ 12 months. 44 patients (24 
women; age 53.5±4.8 years) following acutely successful PVC ablation with long-term follow-up 
were studied. At a mean of 36±6 months, overall long-term ablation success was 75% (33/44 
patients). Notably, recurrence of the targeted PVC focus was low (6.8%, 3/44 patients); the 
majority of recurrences were from a new source location (18.2%, 8/44 patients). The time course 
for targeted versus de novo PVC recurrences was significantly different: recurrence of a PVC 
similar to the targeted PVC morphology occurred at a mean of 5.0±2.0 months, while recurrence 
of a PVC different from the index case occurred at a mean of 35.8±17.1 months (p=0.01). 
Nonischemic cardiomyopathy was associated with increased risk of PVC recurrence (odds ratio 
[OR] 18.43 (95% confidence interval [CI] 1.69-201.1, p=0.02)), while RVOT location at index 
procedure was associated with reduced probability of PVC recurrence (OR 0.06 (95% CI 0.004-
0.89, p=0.04). 
Conclusions: 
The majority of long-term PVC recurrences occur late in follow-up, at locations remote from the 
targeted PVC source or sources. Such sites may represent ongoing substrate evolution; additional 
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work is required to determine the precise substrate alterations which promote such arrhythmogenic 
changes. 
 
  
  
Lee et al., Long Term PVC Recurrence 
 
  4 
Key Words: 
Premature Ventricular Contractions 
Ablation 
Long Term Follow-up 
 
Abbreviations: 
Electrocardiogram:  ECG 
Premature Ventricular Contraction: PVC 
Right Ventricular Outflow Tract: RVOT 
Left Ventricular Outflow Tract: LVOT
Lee et al., Long Term PVC Recurrence 
 
  5 
Introduction 
Frequent premature ventricular contractions (PVC) are common and may occur in 1-4% 
of the general population1.  An elevated PVC burden may cause significant palpitations and lead 
to left ventricular dysfunction or enlargement1-5. Prior seminal work has demonstrated that 
catheter ablation of PVCs is feasible, safe, and may reverse LV dysfunction due to tachycardia-
mediated cardiomyopathy. Current guidelines recommend PVC ablation for drug-refractory 
cases of symptoms or LV dysfunction5-20.  
The success of PVC ablation at 6 months has been reported as 80-95%. However, limited 
data exist regarding the outcomes of PVC ablation beyond 1 year. Additionally, risk factors for 
late PVC recurrence are uncertain. We hypothesized that ongoing substrate changes may result in 
late PVC recurrences at sites remote from the index procedure. The purpose of this study was to 
investigate the mode and timing of long-term PVC recurrence following successful ablation. 
 
Methods  
Study design 
This study was conducted under an institution review board-approved protocol for the 
retrospective analysis of patients following catheter ablation of PVCs between May 2010 and 
May 2015 at University of California San Diego Medical Center. Data were obtained from the 
UCSD procedural database (Perminova, Inc., San Diego, CA, USA) and electronic medical 
record (Epic Systems Corporation, Verona, WI, USA). 
 
Patient Characteristics 
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Patients with a high PVC burden and either symptoms or reduced ejection fraction who 
underwent acutely successful ablation with long-term follow-up greater than or equal to 12 
months were included. Acutely successful ablation was defined as elimination of PVCs without 
intraoperative recurrence on or off an isoproterenol challenge. Recurrence was defined as any of 
the following: recurrent symptoms due to PVCs at clinical follow-up, ECGs demonstrating PVC 
recurrence during follow-up visits, or ambulatory monitors (24/48 Holter, 2 week event 
monitoring) showing >1% PVC burden. Patients were excluded if clinical follow-up was less 
than 12 months. 
 
Mapping and ablation 
A standard electrophysiology study was performed in all patients. Monitored anesthesia 
care was used to avoid PVC suppression by general anesthesia. Three dimensional 
electroanatomic mapping was used in all subjects. PVC mapping and ablation technique and 
equipment were left to the discretion of the attending electrophysiologist. 
In general, the clinical PVC templates were captured for pace-map matching prior to 
sedation. If no PVCs were seen at baseline, then isoproterenol and/or phenylephrine was given to 
induce PVCs.   A combination of pace-map matching and activation mapping was performed 
when possible to localize PVC sources. After successful ablation of the PVC site, a 30-minute 
waiting period was observed, during which high dose isoproterenol (up to 30mcg/min) was 
administered. Ablation success was defined as absence of intra-procedural PVC recurrence. 
 
Comparison of Index versus Recurrent PVC Source Locations 
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Index source locations were identified as the site of PVC termination from 
intraprocedural mapping and ablation. If the patients had clinical recurrence of PVCs during long 
term follow-up, recurrent source location was similarly defined as the site of successful PVC 
termination during repeat ablation. If repeat ablation was not pursued, source location was 
determined using standard 12-lead ECG PVC localization technique2, 4, 11, 12, 17, 19-30.   
For statistical analysis, PVC sources were grouped into the following four categories: (1) 
right ventricular outflow tract (RVOT), (2) right ventricle (non-outflow tract), (3) left ventricular 
outflow tract and coronary cusps (LVOT), and (4) left ventricle (non-outflow tract).  
 
Statistical analysis 
Continuous variables were expressed as mean ± standard deviation and were compared 
with Student’s t-test. Categorical variables were compared with the χ2 test; Fisher’s exact test 
was used when expected values in contingency tables were less than 5. One-way ANOVA was 
used to determine the effect of source location on probability of PVC recurrence, using 
Bonferroni correction for multiple comparisons. Multivariate logistic regression was used to 
determine predictors which were associated with PVC recurrence. Predictors exhibiting 
differences between groups with a p value of <0.05 in the univariate analysis were incorporated 
into the multivariate model.  A two-tailed p value of <0.05 was considered statistically 
significant. Statistical analysis was performed using Stata (Statacorp, College Station, TX, USA). 
 
Results 
The study included 44 patients (age 53.5±4.8 years, 24 female) with acutely successful 
PVC ablation and greater than or equal to 12 months of clinical follow-up. Mean ejection 
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fraction was 56.4±3.8%. PVC burden by Holter monitoring was reduced from mean 19.7±3.3% 
to mean 2.3±1.7% PVCs following successful ablation. Patient characteristics were similar 
between the long-term ablation success and failure groups for age, co-morbidities, 
echocardiographic parameters, and antiarrhythmic drugs (Table 1).  
Long-term ablation success (mean follow-up time after index ablation 36.1±5.9 months) 
of the index PVC was achieved in 93.2% (41/44) of the cases.  8/44 (18.2%) had symptomatic 
recurrence from different PVC from the index case. Thus, overall 3-year freedom from PVCs 
was 75% (33/44) following ablation. To date, 8 of 11 patients with PVC recurrence (72.7%) have 
presented for repeat ablation.   
 
Index PVC Source Location and Procedural Success 
The most common PVC source locations identified and ablated were RVOT (50%) and 
LVOT/coronary cusps (30%, Table 2). The RVOT source location had a 95% (21/22) long-term 
ablation success rate.  
 
Mode, Location, and Time Course of PVC Recurrence 
Three patients (3/44, 6.8%) had recurrence of the index procedure PVC location at a 
mean 5.0 +/- 2.0 months.  Of the three recurrences of the same PVC, 2/3 were from the 
LVOT/coronary cusp and 1 in the RVOT. In contrast, 8 patients (8/44, 18.2%) presented with 
recurrence of a PVC source location distinct from the index procedure at a mean on 35.8 +/- 17.1 
months (p=.01), Table 3. The average annual risk of new PVC source development was 6.1%.  
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Of the 8 patients with recurrence of a new PVC, the LVOT/coronary cusp location during 
the index case (4/8, 50%) was most common.  None of the recurrent PVC sources were identified 
or mapped during the index procedure. 
 
Univariate Analyses 
Univariate analyses of baseline characteristics identified 2 predictors of PVC recurrence 
or non-recurrence (Table 4). Non-ischemic cardiomyopathy was associated with a greater than 5-
fold risk of PVC recurrence (RR of 5.29, 95% CI 1.71-16.3, p=0.01), while RVOT source 
location was associated with a lower risk (RR of 0.14, 95% CI (0.02-0.98), p=0.04). 
 
Multivariate Analyses 
Non-ischemic cardiomyopathy and RVOT source location remained statistically 
significant in multivariate analysis (Table 5). Non-ischemic cardiomyopathy significantly 
increased the odds of PVC recurrence (OR 18.43, 95% CI 1.69-201.1, p=0.02). RVOT location 
at index procedure decreased the odds of PVC recurrence (OR 0.06, 95% CI 0.004-0.89, 
p=0.04). 
 
Comparison of Patients With and Without Long Term Follow-up 
We evaluated whether there were differences between patients with and without long-
term follow-up following PVC ablation. Results are detailed in the online supplement, Table S1. 
In summary, there were no observed differences between groups. 
 
Discussion 
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There are 3 major findings from this long-term study of PVC ablation outcomes. First, we 
found that while the long-term freedom from the index PVC focus remains excellent at 3 years 
(approximately 93%), the majority of PVC recurrences at 3 years were due to new foci 
developing remote from the targeted site (18%). Second, we found that the recurrence of the 
index PVC focus primarily occurs within the first 6 months, while new PVC source development 
occurs after 6 months, at a rate of approximately 6.1% per year. Third, we found that non-
ischemic cardiomyopathy is a significant risk factor for PVC recurrence after ablation, while 
patients with RVOT PVCs enjoyed greater freedom from PVCs after their procedure. These 
findings represent novel insight into the natural history of PVCs following ablation, and may 
help to inform decisions for patients undergoing this procedure. 
 
Long-Term PVC Ablation Outcomes 
Since the seminal studies of PVC ablation, the excellent acute success of the procedure 
has been well documented2, 4. Baser and colleagues reported an 80% success at 3 months in a 
general population undergoing PVC ablation 31. In a study limited to RVOT PVC ablation, 
Zhang and colleagues found an 86.8% long-term success.32 However, the long-term results, 
modes, and timings of recurrence in a general population undergoing PVC ablation remained 
uncertain.  
In this study, we focused on patients presenting with high PVC burdens and either 
symptoms or reduced ejection fractions who had acute procedural success and long-term follow-
up (≥12 months).  During extended follow-up, we found that recurrence of the original PVC 
source remains low, <7%.  These results suggest durable long-term success for most patients 
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undergoing PVC ablation which continues long beyond the previously reported studies of 3-12 
months.  
Importantly, with extended long-term follow we found a significant amount (18.2%) of 
patients had symptomatic PVC recurrence from a different PVC location. None of these 
recurrent PVCs were identified or mapped during the initial ablation. Because the identified 
anatomic locations were distant from the index PVC source, our work strongly supports that they 
are not the result of “changing the exit” from the index procedure, but rather likely represent 
ongoing changes in ventricular substrate. The precise changes and factors underlying such 
progression require further study in order to develop effective therapies to prevent such 
alterations. 
 
Time course of PVC Recurrence 
 The limited follow-up in prior work had not detailed the time course or mode of PVC 
recurrence following successful catheter ablation. As a result, it had been unclear whether such 
cases represented ablation failure or development of new sources.  
In this work, we methodically localized index PVC sources and compared these sites with 
those of recurrent PVCs. We were thus able to identify a bimodal pattern for the mechanism of 
PVC recurrence following ablation. Early in follow-up, recurrent PVCs are most likely to be due 
to resumption of activity of the index PVC site. This may represent an incomplete, or “missed” 
ablation in which ablation stunned or suppressed the PVC source, but did not completely 
eliminate triggering tissue, similar to studies of atrial fibrillation source ablation33.   
In contrast, de novo sources predominate in late PVC recurrence, consistent with work in 
other arrhythmias supporting a link between ongoing substrate remodeling and arrhythmia risk34. 
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Such data are useful in counseling patients regarding PVC ablation. Furthermore, this finding 
may be hypothesis generating in that future work may study lifestyle interventions and risk factor 
modifications to potentially slow or prevent subsequent PVC source development, as has been 
shown in AF35.  
 
Risk Factors for PVC Recurrence 
Finally, we analyzed clinical factors associated with greater and reduced risk of PVC 
recurrence. Notably, patients with non-ischemic cardiomyopathy, defined as reduced ejection 
fraction without patient history of myocardial infarction or echocardiographic evidence of 
regional scar, are significantly more likely to have PVC recurrence. This finding is consistent 
with prior work in PVC ablation demonstrating that PVC sources were often associated with 
remodeled substrate36. Notably, prior work has demonstrated that the ventricles of patients with 
non-ischemic cardiomyopathy are significantly remodeled37and have elevated levels of 
biomarkers associated with myocyte stretch and necrosis38 compared with patients without non-
ischemic cardiomyopathy. Thus, substrate progression in such patients may occur at an 
accelerated rate, and is thus detectable in our cohort of patients during the timescale of this study.  
In contrast, PVC recurrence is reduced in patients with initial RVOT source location. 
PVCs from a patient with idiopathic RVOT PVCs have been previously shown to be a cyclic-
AMP mediated process2, 4, 13, 39-42, rather than related to fibrosis and scar. Thus, such patients may 
not be at risk for accelerated substrate evolution and PVC recurrence at a mean follow-up of 3 
years.   
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These factors may play an important role in pre-ablation counseling and education as 
they represent clinical characteristics that predict PVC recurrence. Such data can help inform a 
more precise discussion of the expected success rate of an invasive PVC ablation.  
 
Limitations 
The main limitation of this study was a small study population due to our strict inclusion 
criteria of a minimum of 12 months of follow-up after successful PVC ablation. Despite this 
limitation, we were able to identify sufficient patients to detect the bimodal pattern and timing of 
PVC recurrence (e.g. index versus de novo). Furthermore, there was no statistical difference in 
our database between patients who did and did not have long-term follow-up. This provides 
reassurance regarding the generalizability of our findings. Ongoing prospective series are 
required to confirm these results. 
 
Conclusions 
Long-term success of PVC ablation is good; the majority of patients remain PVC free at a 
mean follow-up of 3 years. Most recurrences after the first year occur at a site anatomically distinct 
from the targeted focus. Non-ischemic cardiomyopathy is associated with increased PVC 
recurrence, while RVOT location is associated with decreased probability of PVC recurrence. 
 
 
Lee et al., Long Term PVC Recurrence 
 
  14 
Table 1: Patient Characteristics and Long-Term Ablation Outcome 
 
Characteristics 
Successful Long-
term Outcome 
Unsuccessful Long-
term Outcome p value 
Patients, n 33 11  
Women/men 20/13 4/7 0.29 
Age (years, ±SD) 53.4±5.6 53.9±9.2 0.92 
LV EF (%, ±SD) 58.0±4.3 52.3±.7.0 0.35 
Pre-ablation PVC 
Burden (%, ±SD)  
21.1±8.9 19.2±3.5 0.60 
Ischemic CMP (n, %) 2 (6%) 2 (18%) 0.3 
NICM (n, %) 3 (9%) 4 (36%) 0.07 
Hypertension (n, %) 14 (42%) 3 (27%) 0.32 
Diabetes Mellitus (n, 
%) 
4 (12%) 1 (9%) 1 
Dyslipidemia (n, %) 12 (36%) 2 (18%) 0.28 
CAD (n. %) 6 (18%) 2 (18%) 1 
Medications: 
Antiarrhythmics pre-
ablation (n, %) 
4 (12%) 0 0.32 
Antiarrhythmics post-
ablation (n, %) 
4 (12%) 0 0.32 
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Table 2: PVC Source Location and Ablation Success 
 
Index PVC Source Location 
Successful Long-term 
Outcome  
LVOT, including Coronary 
Cusps † 
7/13 (54%) 
a. LVOT (n, %) 3/6 (50%) 
b. Coronary cusps (n, %) 4/7 (57%) 
 
 
Left Ventricular 5/7 (71%) 
a. Mitral annulus (n, %) 2/3 (67%) 
b. Mid posterior LV (n, %) 2/2 (100%) 
c. Septal basal LV (n, %) 1/1 (100%) 
d. Anterolateral papillary muscle 
base (n, %) 
1/1 (100%) 
 
 
RVOT († p=0.001) 21/22 (95%) 
 
 
Right Ventricular 0/2 (0%) 
a. Tricuspid annulus 0/1 (0%) 
b. Anterior apical RV wall 0/1 (0%) 
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Table 3: PVC Recurrence at Similar vs. Distant Source Locations  
 
Recurrence at Similar Source Location Compared with Index Ablation 
Patient 
Age 
(years) 
Initial source 
location 
Recurrent source 
location  
Timing of 
Recurrence 
1 41 
Left coronary 
cusp 
similar 6 months 
2 51 LVOT similar 3 months 
3 44 
Anterior apical 
RV wall 
similar 6 months 
Recurrence at Distant Source Location Compared with Index Ablation 
Patient 
Age 
(years) 
Initial source 
location 
Recurrent source 
location  
Timing of 
Recurrence 
1 64 
LVOT/Left 
coronary cusp 
Posterior basal septal 
RV 
54 months 
2 55 
Left coronary 
cusp 
RVOT free wall 58 months 
3 31 Anterior TVA 
RVOT under 
pulmonic valve 
48 months 
4 60 LVOT 
R/L JXN Left/right 
coronary cusp 
46 months 
5 55 Superior MVA RVOT 6 months 
6 77 
Posteroseptal 
RVOT 
Mid-posterior LV 39 months 
7 59 Mid-posterior LV RVOT posterior wall 33 months 
8 52 
Left coronary 
cusp 
Posterior medial 
papillary muscle + 
anterolateral basal 
LV 
2 months 
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Table 4: Predictors of Recurrence: Univariate Analysis 
 
Characteristic  RR 95% CI p-value 
Male 3.60 0.81-15.9 0.11 
Reduced ejection 
fraction (EF<50) 0.71 0.09-5.34 0.74 
ICM 3.33 0.98-11.4 0.15 
NICM 5.29 1.71-16.3 0.01 
HTN 0.53 0.12-2.33 0.45 
DM 1.11 0.17-7.28 1.00 
HLD 0.31 0.04-2.26 0.25 
CAD 1.50 0.37-6.11 0.62 
PVC Sources    
  LVOT+cusp 2.38 0.70-8.12 0.21 
  RVOT 0.14 0.02-0.98 0.04 
  LV not OT 1.76 0.44-7.01 0.6 
  RV not OT 3.00 0.64-14.0 0.33 
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Table 5: Predictors of Recurrence: Multivariate Analysis 
 
Characteristic* OR 95% CI  p-value 
NICM 18.43 1.69-201.1 0.02 
RVOT 0.06 0.004-0.89 0.04 
 
*Only variables exhibiting differences between groups with a p value of <0.05 in the univariate 
analysis were incorporated into the multivariate model. 
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Differences Between Patients With and Without Long-Term Follow-up 
 To address the possibility of significant differences between patients with (≥12 months) 
and without (<12 months) long-term follow-up, we compared available demographic information 
for the two groups. Data are summarized in table S1, below.  
 
Table S1: Comparison of Excluded Patients (<12 months of follow-up) and Study Patients 
 
Characteristics 
<12 months of 
follow-up 
≥12 months of 
follow-up p value 
Patients, n 27 44  
Women/men 11/16 24/20 0.26 
Age (years, ±SD) 56.6±10.2 53.5±4.7 0.45 
LV EF (%, ±SD) 57.9±4.7 56.4±3.8 0.63 
Ischemic CMP (n, %) 0  4 (9%) 0.16 
NICM (n, %) 4 (15%) 7 (16%) 1.00 
Hypertension (n, %) 12 (44%) 17 (39%) 0.63 
Diabetes Mellitus (n, 
%) 
1 (4%) 5 (11%) 0.40 
Dyslipidemia (n, %) 9 (33%) 14 (32%) 0.89 
CAD (n. %) 4 (15%) 8 (18%) 0.76 
Medications: 
Antiarrhythmics pre-
ablation (n, %) 
4 (15%) 4 (9%) 0.47 
Antiarrhythmics post-
ablation (n, %) 
3 (11%) 4 (9%) 1.00 
 
 In summary, there were no significant differences between the two groups. Notably, the 
characteristics of both groups are consistent with those reported in contemporary studies of PVC 
ablation1. 
 This similarity between groups addresses concern regarding bias present in the studied 
population. Because patients with recurrent symptoms are more likely to have ongoing, long-
term follow-up, our study thus represents an upper limit for the rate of PVC recurrence. 
However, because the studied population is similar to excluded patients, and similar to 
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contemporary cohorts undergoing PVC ablation, our findings are more likely to be generalizable 
to contemporary practices who treat such patients. 
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